---
figid: PMC8253981__DDDT-15-2815-g0002
figtitle: 'Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence
  to Date'
organisms:
- Escherichia coli
- Staphylococcus aureus
- Mycobacterium tuberculosis
- Helicobacter pylori
- Streptococcus pneumoniae
- Clostridioides difficile
- Enterococcus faecalis
- Mycobacterium tuberculosis variant bovis BCG
- Streptococcus pyogenes
- Haemophilus influenzae
- Bacteroides fragilis
- Mycolicibacterium smegmatis
- Fusobacterium nucleatum
- Lactobacillus acidophilus
- Staphylococcus epidermidis
- Bifidobacterium longum
- Enterococcus faecium
- Mycobacterium leprae
- Enterobacter cloacae
- Cutibacterium acnes
- Moraxella bovis
- Mycobacterium avium complex sp.
- Moraxella catarrhalis
- Mycobacterium kansasii
- Mycolicibacterium phlei
- Mycolicibacterium fortuitum
- Mycobacterium tuberculosis variant africanum
- Veillonella parvula
- Parvimonas micra
- Mycobacterium ulcerans
- Gardnerella vaginalis
- Mycobacterium canettii
- Porphyromonas asaccharolytica
- Mycobacterium tuberculosis variant pinnipedii
- Prevotella bivia
- Mobiluncus mulieris
- Mus musculus
- Rattus norvegicus
- Cavia porcellus
- Cricetulus griseus
- Homo sapiens
- Macaca fascicularis
- Oryctolagus cuniculus
- Candida albicans
organisms_ner:
- NA
pmcid: PMC8253981
filename: DDDT-15-2815-g0002.jpg
figlink: /pmc/articles/PMC8253981/figure/f0002/
number: F2
caption: (A) Intracellular activation pathway for nitroimidazoles. (B) Keto mycolic
  acid synthesis pathway. Pretomanid blocks formation of keto mycolic acids, a component
  of the cell wall, by impairing oxidation of precursor, hydroxymycolic acid.
papertitle: 'Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence
  to Date.'
reftext: Stephani L Stancil, et al. Drug Des Devel Ther. 2021;15:2815-2830.
year: '2021'
doi: 10.2147/DDDT.S281639
journal_title: Drug Design, Development and Therapy
journal_nlm_ta: Drug Des Devel Ther
publisher_name: Dove
keywords: pretomanid | tuberculosis | antimicrobial | multi-drug resistant
automl_pathway: 0.9256161
figid_alias: PMC8253981__F2
figtype: Figure
redirect_from: /figures/PMC8253981__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8253981__DDDT-15-2815-g0002.html
  '@type': Dataset
  description: (A) Intracellular activation pathway for nitroimidazoles. (B) Keto
    mycolic acid synthesis pathway. Pretomanid blocks formation of keto mycolic acids,
    a component of the cell wall, by impairing oxidation of precursor, hydroxymycolic
    acid.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - glucose-6-phosphate
  - PEPFO
  - NO2
  - nitro
  - hydroxymycolic acids
  - 6-phosphoglucolactone
  - 'NO'
  - nitroso
  - HNO2
  - ketomycolic acids
  - ribulose-5-phosphate
  - hydronitroxide
  - NHOH
  - hydroxylamine
  - methylglyoxal
  - NH2
  - amino
  - amine
---
